Kyle Doherty

Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.

Robert J. Motzer, MD, reviews the need for increased studies on the use of immunotherapy in later-line settings for advanced renal cell carcinoma.

Trastuzumab deruxtecan may become a new therapy option for patients with HER2-positive tumors, according to an expert from The University of Texas MD Anderson Cancer Center.

SWOG S1826 is an open-label trial that enrolled patients with newly diagnosed stage III or IV classical Hodgkin lymphoma who were randomly assigned to receive either nivolumab/AVD or brentuximab vedotin/AVD.

Patients with highly transfusion dependent, relapsed/refractory myelodysplastic syndrome appear to have long-lasting transfusion independence and increased hemoglobin following treatment with imetelstat.

Results from the phase 3 NATALEE trial investigating ribociclib plus endocrine therapy may change practice for the treatment of hormone receptor–positive or HER2-negative early breast cancer, according to an expert from the University of Chicago Medicine.

HER-Vaxx with standard-of-care chemotherapy yielded benefit in patients with HER2-overexpressing metastatic or advanced gastric/gastroesophaeal junction adenocarcinoma.

Trastuzumab deruxtecan improved survival outcomes vs trastuzumab emtasine in patients with HER2-positive breast cancer, according to updated results from the DESTINY-Breast03 trial.

Data from the phase 1 METEOR-1 trial showed modest efficacy with GSK3326595, a PRMT5 inhibitor, in patients with advanced solid tumors.

Results from a presentation at 2022 ESMO showed DCC-3116 was tolerated in patients with RAS or RAF-mutant solid tumors.

Results of a phase 2 trial show favorable efficacy and tolerable safety of naporafenib in combination with rineterkib, trametinib, or ribociclib in previously treated, unresectable or metastatic melanoma.

CLDN6-directed CAR T-cell therapy BNT211-01 showed clinical activity as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in relapsed/refractory advanced solid tumors.

Patients with non–small cell lung cancer previously treated with multiple lines of therapy may benefit from treatment with patritumab deruxtecan.

Ifosfamide leads to slightly better event-free and overall survival vs topotecan/cyclophosphamide in relapsed or refractory Ewing sarcoma.

At 2022 ASCO, final survival data from the phase 3 PALOMA-2 trial confirmed similar survival between palbociclib plus letrozole and letrozole alone.

Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.

Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.

A significant proportion of patients with nonclonal ductal carcinoma in situ were found to have recurrence that was not genetically linked to the primary tumor.

Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.

Data presented at 2022 SGO from the phase 2 OVARIO trial show promise of niraparib plus bevacizumab in high-risk ovarian cancer treated with frontline platinum-based chemotherapy.

Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.

Daniel P. Petrylak, MD, reviews the current systemic therapy treatment paradigm in metastatic urothelial carcinoma.

Patients with metastatic castration-sensitive prostate cancer experienced an early and robust reduction in prostate-specific antigen of 90% or more following treatment with apalutamide vs enzalutamide.

YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

A quality-of-life analysis from the phase 3 ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma shows favorability of the CAR T-cell therapy over standard options.

Patients with relapsed or refractory follicular lymphoma who had been given 2 or more prior lines of therapy and received tisagenlecleucel saw positive efficacy responses.

Second-line treatment with liscocabtagene maraleucel improved survival compared with the standard of care for patients with relapsed or refractory large B-cell lymphoma.

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Results of a single-arm study indicate that patients with previously treated metastatic cervical cancer may derive benefit from treatment with balstilimab plus zalifrelimab.